Personalis (NASDAQ:PSNL - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Needham & Company LLC in a report issued on Thursday, Benzinga reports. They currently have a $3.50 target price on the stock. Needham & Company LLC's price objective indicates a potential upside of 155.47% from the company's previous close.
Personalis Price Performance
Shares of Personalis stock traded down $0.01 during midday trading on Thursday, reaching $1.37. The company had a trading volume of 130,376 shares, compared to its average volume of 390,797. The stock has a fifty day moving average price of $1.44 and a 200 day moving average price of $1.42. The firm has a market cap of $69.19 million, a PE ratio of -0.61 and a beta of 1.95. Personalis has a fifty-two week low of $0.89 and a fifty-two week high of $3.27.
Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $19.68 million during the quarter, compared to the consensus estimate of $19.56 million. Personalis had a negative return on equity of 61.42% and a negative net margin of 147.38%. As a group, sell-side analysts forecast that Personalis will post -1.58 EPS for the current year.
Institutional Investors Weigh In On Personalis
Hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its holdings in shares of Personalis by 16.6% during the fourth quarter. ARK Investment Management LLC now owns 6,671,545 shares of the company's stock valued at $14,010,000 after acquiring an additional 952,118 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Personalis by 3.4% during the first quarter. BlackRock Inc. now owns 4,538,555 shares of the company's stock valued at $37,171,000 after acquiring an additional 149,222 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Personalis by 3.6% during the first quarter. JPMorgan Chase & Co. now owns 3,627,721 shares of the company's stock valued at $10,012,000 after acquiring an additional 124,482 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Personalis by 14.6% during the third quarter. Vanguard Group Inc. now owns 2,063,888 shares of the company's stock valued at $6,130,000 after acquiring an additional 263,211 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its holdings in shares of Personalis by 7.2% during the first quarter. Alyeska Investment Group L.P. now owns 1,245,668 shares of the company's stock valued at $3,438,000 after acquiring an additional 83,996 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.
About Personalis
(
Get Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Further Reading
Before you consider Personalis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.
While Personalis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
